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Abstract Sumatriptan, a relatively hydrophilic triptan,
based on several animal studies has been regarded to be
unable to cross the blood–brain barrier (BBB). In more
recent animal studies there are strong indications that
sumatriptan to some extent can cross the BBB. The CNS
adverse events of sumatriptan in migraine patients and
normal volunteers also indicate a more general effect of
sumatriptan on CNS indicating that the drug can cross the
BBB in man. It has been discussed whether a defect in the
BBB during migraine attacks could be responsible for a
possible central effect of sumatriptan in migraine. This
review suggests that there is no need for a breakdown in the
BBB to occur in order to explain a possible central CNS
effect of sumatriptan.
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Introduction
The triptans, 5-HT1B/1D receptor agonists, are effective
drugs in the treatment of migraine attacks [1–4]. It has been
debated for a long time whether the triptans act during
migraine attacks on the peripheral nociceptive input or on
the nociceptive system in the CNS [5, 6]. Triptans can
theoretically decrease peripheral nociception either by a
selective cranial vasoconstriction, the rationale for its
development [6, 7] or an effect on trigeminovascular nerves
[6]. A peripheral effect on trigeminal vascular nerves was
indicated by the blocking effect of sumatriptan of neuro-
genically mediated plasma extravasation [8]. Inhibitors of
neurogenic inflammation (NI) were, however, ineffective in
the treatment of migraine [9] and it is thus difficult to
ascribe a pivotal role for NI in migraine. In 1996 it was,
based on the effect of zolmitriptan, suggested that inhibition
of trigeminal neurons in the brain stem by lipophilic triptans
may play a role in the anti-migraine effect of these drugs
and that these results offered the prospect of a third path-
ophysiological target site for triptans [10].
The prototype of a triptan is sumatriptan, the first devel-
oped triptan [7]. Apparently this drug, which is relatively
hydrophilic, did not in several animal studies [5, 11–14]
cross the blood–brain barrier (BBB) in sufficient amount to
cause a pharmacological effect in the trigeminal nucleus
caudalis [5, 12, 13] or frontal cortex [11]. In contrast, other
more lipophilic triptans, such as zolmitriptan [5, 15], nara-
triptan [16], rizatriptan [17], and eletriptan [18], caused an
inhibition of nociception in the trigeminal nucleus caudalis
in these animal models of migraine.
In contrast to earlier studies [7, 19] it was recently stated
that ‘‘this central site of action is consistent with the evi-
dence that sumatriptan can rapidly cross the blood–brain
barrier into the central nervous system after systemic
administration’’. This was, however, based on a pharma-
cokinetic study using sumatriptan 3.2 mg/kg [20] far above
the therapeutic dose of 100 lg/kg.
In recent studies from 2004 and 2009 a presynaptic
inhibition of sumatriptan (300–600 lg/kg) in the trigeminal
nucleus caudalis was found [21] and reversal of facial
allodynia by sumatriptan [22] was observed.
In the following, animal studies on sumatriptan will be
reviewed and possible explanation for the discrepancy
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among studies will be suggested. Next, CNS adverse events
after triptans in migraine patients and normal subjects will
be reviewed.
It is concluded that both the animal and the human
studies suggest that sumatriptan to some minor extent can
penetrate into the CNS across the BBB both in animals and
in man. The minor penetration of sumatriptan into the CNS
is, however, sufficient to cause pharmacological effects
most likely because the drug is potent 5-HT1B/1D receptor
agonist [1, 3].
Review of studies in animals
The penetration of systemically administered 14C-labeled
sumatriptan into the central nervous system was investi-
gated in the mouse [7]. Only 0.006% of total radioactivity
was found in the brain indicating poor brain penetration by
sumatriptan [7]. In another study no sumatriptan was found
in the brain with whole body assay in rats [19].
An overview of 21 animal studies investigating the
possible effect of sumatriptan on the CNS is presented in
the Table 1. For an overview of used animal models of
migraine, see [23].
The clinically used dose of subcutaneous sumatriptan
6 mg corresponds to approximately 100 lg/kg, but the
dose used in animal studies varied widely from 50 lg/kg to
100 mg/kg (Table 1). In nine studies [5, 11–14, 24–27],
there was no effect of sumatriptan in the animal model.
In one study an antinociceptive effect was found after
5–30 mg/kg, most likely mediated by the 5-HT1A receptor
[28]. In contrast, an effect of sumatriptan 100–1,000 lg/kg
on the CNS was found in nine studies [21, 22, 29–35].
In one study sumatriptan 300 lg/kg blocked c-fos
protein-like immunoreactivity within trigeminal nucleus
caudalis following irritation of meningeal afferents induced
by blood [36]. In another study from the same group of
investigators sumatriptan 300 lg/kg reduced c-fos protein-
like immunoreactivity in the trigeminal nucleus caudalis
(TNC) after repeated cortical spreading depression [37]. In
the authors opinion the effects of sumatriptan were most
likely due to an effect on the peripheral part of the afferent
fibres of the trigeminal nerve but they add: ‘‘of course, the
studies reported herein do not exclude the unlikely possi-
bility that this hydrophilic 5-HT analogue blocks c-fos
protein-like immunoreactibility within the TNC directly’’
[37].
In a later study from 1997 with the same problem it was
found that morphine 3 mg/kg, but not sumatriptan 300 lg/
kg, decreased c-fos expression in TNC after multiple CSD
[27]. These results have been disputed [38].
In one study sumatriptan acutely in a dose of 100 lg/kg
and 1 mg/kg, as well as zolmitriptan 100 lg/kg, decreased
5-HT synthesis rate in many brain region in rats including
the dorsal raphe nucleus [34]. Chronically, sumatriptan
(300 lg/kg per day) induced significant increases in the
5-HT synthesis rate in many projection areas but had no
effect in the dorsal raphe nucleus [33]. Overall, these
findings indicate that not only zolmitriptan, but also
sumatriptan affect brain serotonergic neurotransmission
[34].
One study used very high doses of sumatriptan: in a
pharmacokinetic–pharmacodynamic study in rats from
2001 [20] on the serotonergic effects and extracellular
levels of eletriptan, zolmitriptan and sumatriptan, using a
very high dose of 2.5 mg/kg i.v., it was shown that the
three drugs with different lipophilicity had similar extra-
cellular levels in the brain. On the other hand, sumatriptan
did not exert a serotonergic effect, as did zolmitriptan and
eletriptan, most likely because sumatriptan is less potent in
this system than the two other triptans [20]. In addition,
non-equipotent doses of the two triptans compared with
sumatriptan were used, see later. The problem with this
study is evident: the usual subcutaneous dose of suma-
triptan in man is 6 mg, corresponding to 100 lg/kg,
whereas the dose is 32 times higher in this rat study [20].
This could indicate that a saturable, expulsion process
limiting the access of the three triptans to the CNS exists.
In fact, eletriptan distribution in the CNS is limited by the
P-glycoprotein-mediated efflux [39, 40] whereas suma-
triptan and zolmitriptan are subjected to non-P-glycopro-
tein-mediated efflux [41].
What could be the explanation for this different effect of
sumatriptan in these various animal models of migraine? In
two of these studies in which sumatriptan had no effect [12,
13], an effect of sumatriptan was observed after disruption
of the BBB with mannitol. The potential for a CNS effect
of a triptan, including sumatriptan, is thus present in the
animal models used [12, 13] as also demonstrated by the
effect of zolmitriptan [5, 15], naratriptan [16], rizatriptan
[17] and eletriptan [18] in these models with intact BBB.
The dictum was thus in the beginning, based on phar-
macokinetic studies [7, 19] that sumatriptan had only
minimal or no passage within the central nervous system.
Most early animal studies apparently supported, with dif-
ferent methodology, the lack of penetration of sumatriptan
across the BBB [11–13, 24]. Later animal studies have
shown in some but not in all (Table 1) investigations that
sumatriptan in these animal models, mostly of migraine,
did exert an effect inside the BBB.
CNS effects in migraine patients and other subjects
In human postmortem brains [3H]sumatriptan binding sites
have been found in among others, globus pallidus [
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Table 1 Studies on the central nervous system effect of sumatriptan in animals
References Dose of
sumatriptan






50 and 500 lg/kg
(i.p.) (guinea pig)
Extracellular 5-HT levels in the frontal cortex as
measured by microdialysis
No effect of systemic
sumatriptan (sumatriptan
10-8–10-7 M in microlysate






Antinociceptive effect by (various tests) No antinociceptive effect







c-fos expression in the trigeminal nucleus caudalis
after autologous blood in cisterna magna
Sumatriptan reduced c-fos
positive cells in trigeminal














100 lg/kg (cat) Single units activity and trigeminal somatosensory
evoked potentials after SSS stimulation









1,000 lg/kg (rat) Expression of c-fos mRNA in trigeminal nucleus
caudalis after stimulation of trigeminal ganglion










5–30 mg/kg (mouse)) Antinociceptive effect (hot-plate test) There was an antinociceptive
effect, most likely mediated












85 lg/kg (cat) c-fos expression in trigeminal nucleus caudalis
after dilatation of SSS





120 lg/kg (rat) c-fos in caudal trigeminal nucleus after stereo
electrical stimulation of the trigeminal ganglion












85 lg/kg (rat) c-fos expression in trigeminal nucleus caudalis
after SSS stimulation
No effect on c-fos expressionb –
Read et al.
(1999) [31]
300 lg/kg (rat) Nitric oxide formation in the cerebral cortex
after nitroglycerin
Decrease of NO formation ?
Read and
Parsons [32]
300 lg/kg (rat and
cat)
Nitric oxide formation in the cerebral after CSD Decrease of NO formation and










3.2 mg/kg (rat) Measurements of sumatriptan concentrations in
microdialysate. Central release of 5-HT
Concentrations of sumatriptan
up to 8 nM was observed. No
effect on central release
of 5-HT
?
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cortex [ hippocampus [42]. In the brain stem the highest
[3H]sumatriptan binding sites were seen in the substantia
nigra, the trigeminal nucleus, nucleus of the tractus soli-
tarius and periaqueductal gray [43]. If sumatriptan can
cross the BBB in sufficient amounts, one would thus expect
CNS adverse events after therapeutic use of the drug.
Some migraine patients complain of sleepiness/tired-
ness, difficulty in thinking and dizziness [44] after suma-
triptan. In a meta-analysis of oral triptans, sumatriptan
100 mg caused 6% (95% CI 3–9%) more CNS adverse
events than placebo [2]. This could indicate a CNS effect
of sumatriptan. Similarly, zolmitriptan 2.5 mg caused 9%
(965 CI 4–14%) more CNS adverse events than placebo
[2]. The CNS adverse events of triptans can, however, be
partly ascribed to migraine symptoms being unmasked by
effective treatment since responders to eletriptan had more
CNS AEs than non-responders to eletriptan [45]. However,
in one large RCT [46] any CNS adverse events were more
frequent after sumatriptan 100 mg (29.6%) (n = 386) than
after rizatriptan 10 mg (22.5%) (n = 385) [47] despite the
fact that the two drugs were equipotent for headache relief
after 2 h [46]. In addition, rare cases of central nervous
system AEs such as akathesia, acute dystonia and patho-
logical laughter have been described after subcutaneous
and oral sumatriptan used in the treatment of migraine and
cluster headache [48–50].
That CNS adverse events can occur after triptans outside
migraine attacks was shown in a placebo-controlled study
in female healthy volunteers [51]. The results showed that
sumatriptan 50 mg and rizatriptan 10 mg caused small but
clear effects on the CNS, mainly mild sedative effects,
which were less than sedation after the active control drug,
temazepam 20 mg [51]. In addition, sumatriptan caused a
significant increase in the EEG alpha power compared with
placebo for the frontal leads, whereas this was not the case
for rizatriptan [51]. In another study it was shown that
zolmitriptan 5 and 10 mg, but not sumatriptan 100 mg, had
an effect on cortical auditory-evoked potential in man [52].
In one placebo-controlled study in male subjects with a
history of substance abuse subcutaneous sumatriptan 8 and
16 mg was psychoactive, was discriminated from placebo,
produced a dose-related decrease on euphoria score and
elevated scores on measures of apathic sedation and










100 lg/kg (rat) Mechanical allodynia-like behaviour after ligature
of n. infraorbitalis
A significant reduction of
mechanical allodynia-like
behaviour on injured and




300–1,000 lg/kg (rat) Serotonin synthesis in brain Given acutely a decrease in
5-HT synthesis in certain





600 lg/kg (rat) Nitroglycerin-induced nNOS immunoreactive






300 lg/kg (rat) Changes in spontaneous activity of trigeminal









600 lg/kg (rat) Prevention of facial allodynia after inflammatory






600 lg/kg i.p. and
0.06 lg intrathecal
(mouse)
Prevention of thermal and mechanical allodynia Systemic sumatriptan inhibited





a The authors considered that this was a peripheral effect on the trigeminal nerve [34], see text
b The authors concluded: ‘‘The simplest reasonable conclusion is that sumatriptan inhibited trigeminal afferent by a direct neuronal mechanism
at the peripheral terminal.’’[22]. They found a central effect unlikely because no central effect of sumatriptan was observed in previous studies
[9, 10]
c Zolmitriptan 30 lg/kg caused a decrease in c-fos expression in trigeminal nucleus caudalis
d The site of action is not totally clear but is most likely a CNS effect because a reduction of contralateral allodynia [29]
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therapeutic doses do exert a CNS effect in non-migrainous
subjects.
In a recent positron emission tomographic (PET) study
in six migraine patients, it was shown that subcutaneous
sumatriptan 6 mg normalizes the migraine attack-related
increase in brain serotonin synthesis [54], thus demon-
strating convincingly that sumatriptan can exert an effect
on the brain in migraineurs during an attack.
In a double-blind, placebo-controlled study in migraine
patients, subcutaneous sumatriptan 6 mg caused an
increase of the duration of the early exteroceptive sup-
pression period of temporalis muscle activity both during
the migraine attack and during the migraine interval [55],
whereas there was no effect on contingent negative varia-
tion [56].
In another study on glyceryl trinitrate-induced migraine,
during attacks there was an increase in slow rhythmic
activity of the theta and delta range and a decrease of
activity in the alpha and beta range [57]. The abnormalities
disappeared after a sumatriptan injection [57]. One cannot
exclude, however, that the effect of sumatriptan in this
study is due to an effect on migraine per se.
In one study on obsessive–compulsive disorder (OCD)
the sumatriptan treated subjects’ OCD symptoms worsen-
ing, as measured by The Yale Brown scale, was significant
compared to placebo (p \ 0.02) [58]. In another study no
such effect was observed [59].
Exercise capacity was decreased after subcutaneous
sumatriptan 6 mg in one placebo-controlled study [60].
The authors’ conclusion was that it could be a peripheral
effect of the drug because ‘‘sumatriptan is a selective 5-HT
(1B/1D) receptor agonist that does not cross the blood–
brain barrier’’ [60]. It was thus regarded as an established
fact, based on [12, 13], that sumatriptan does not penetrate
the BBB.
In one review it was concluded that the incidence of
CNS adverse events is correlated (r = 0.68) to the lipo-
philic attributes of the triptans [61], whereas in two other
reviews this was not the case [62, 63]. Re-analysing of the
data from the first review [61] with the use of equipotent
triptan doses sumatriptan 100 mg (instead of 50 mg) and
eletriptan 40 mg (instead of 80 mg) shows, however, that
there is no correlation (r = 0.324, p = 0.438, Spearman’s
nonparametric test), as would be expected since the triptans
are subjected to different efflux systems from the brain
[41].
Overall, the triptans, apart from almotriptan 12.5 mg
and the low dose of naratriptan, 2.5 mg [2], result in CNS
adverse events with a relatively low incidence which
indicates an effect on the CNS. These CNS adverse events
of triptans, especially sleepiness/tiredness, can in some
cases be a problem in the clinical use of the drugs,
including sumatriptan [3].
Comments on the possible effects of sumatriptan
inside the BBB
Are the doses of the different triptans used in these animal
studies comparable? In one study investigating parenteral
sumatriptan and zolmitriptan, it was stated that clinically
comparable doses were used [5]. Thus sumatriptan 85 lg/kg
and zolmitriptan 30 lg/kg were used. There are RCTs
with subcutaneous sumatriptan [64, 65], but none with
parenteral zolmitriptan. Equipotency must therefore be
judged from oral comparative RCTs. Based on one large
comparative RCTs, zolmitriptan 5 mg is comparable with
sumatriptan 100 mg [66]. This is also the case in the well-
known meta-analysis [2]. Thus is seems reasonable to
compare the systemic availability of these doses. Suma-
triptan has an oral bioavailability of 14% [1, 3] and 100 mg
thus results in sumatriptan 14 mg being available, whereas
zolmitriptan 5 mg with an bioavailability of 39% [1, 3]
results in zolmitriptan 1.95 mg being systemically avail-
able. The ratio between the systemically available doses is
thus 7.2. In the animal study [5] of sumatriptan and
zolmitriptan mentioned above, the dose ratio was 85/
30 = 2.8. So either too little sumatriptan or too much
zolmitriptan was used. The sumatriptan 85 lg/kg dose is
near the subcutaneously used dose of 6 mg in man. So most
likely a too high dose of zolmitriptan was used if the two
drugs are equipotent.
The different results for sumatriptan in these animal
models is most likely not a consequence of different doses
of the drug used. Thus, in ‘‘negative’’ studies the dose
range of sumatriptan was 85 lg/kg to 6 mg/kg, whereas in
the ‘‘positive’’ studies the dose range was 100–1,000 lg/kg
(Table 1). The results most likely depend on the animal
model used. Whether an inhibitory CNS effect of suma-
triptan is observed in an animal study is most likely the
result of the ratio between stimulus used, electrical stim-
ulation [5, 13] or inflammatory mediators [20, 21], and the
inhibitory effect of sumatriptan. If the stimulus is very
strong, such as superior sagittal stimulation (SSS), for 1 h
in one study [5] and described in one study as a supra-
maximal stimulation [12] or trigeminal ganglion stimula-
tion [13, 14] even ‘‘normal’’ levels of sumatriptan in the
CNS are most likely unable to inhibit the response. In
contrast, ‘‘more’’ physiological stimuli such as inflamma-
tory mediators [21, 22] can probably be inhibited by
‘‘normal’’ levels of sumatriptan. It should be noted, how-
ever, that the more lipophilic triptans such as zolmitriptan
[5], naratriptan [16], rizatriptan [17] and eletriptan [18]
were effective in the SSS model without a breakdown of
the BBB. This higher efficacy of these triptans than
sumatriptan in this SSS model does not, however, result in
increased effect of these triptans in the acute treatment of
migraine [1, 2].
J Headache Pain (2010) 11:5–12 9
123
The presence of triptan binding sites and triptan receptor
mRNA within the CNS leaves little doubt as to the
potential for CNS effects of the triptans [67–69]. It is
recognized that the triptan class of compounds do generally
have poor penetration characteristics with brain/plasma
partition coefficient (Kp,brain) [41] well below 1, when
compared with typical CNS marketed drugs (e.g. diphen-
hydramine with a Kp,brain of 9) [42]. The Kp,brain in P-
glycoprotein-competent (mdrla ?/?) mice were 0.13
(sumatriptan), 0.42 (naratriptan), 0.20 (rizatriptan),0.038
(zolmitriptan), and 0.30 (eletriptan) [41].
The extent of brain penetration is, however, a poor guide
to central activity, especially with potent agonists such as
the triptans, since they, in contrast to most other CNS
agents that are antagonists, will require only low fractional
receptor occupancy to exert central effects [40].
The original hypothesis when sumatriptan was devel-
oped was that the drug was a specific cranial vasocon-
strictor [6, 7] and that it did not or only to a very minor
extent penetrate across the BBB into the CNS [7, 19]. The
best way to substantiate a hypothesis is to try to falsify it ad
modum Popper [70]. The intended falsifying experiment
should have a suitable design and should be of high quality.
In the present case the hypothesis was that sumatriptan
cannot cross the BBB, and the falsifying experiment would
be an investigation aimed at and demonstrating an effect in
CNS of sumatriptan in an animal and if possible in man.
Until 1996 the investigations failed to unequivocally falsify
the hypothesis (Table 1). Thus in two studies [12, 13] the
BBB had to be broken down by hyperosmolar mannitol
before sumatriptan could exert an inhibitory effect in the
trigeminal nucleus caudalis (TNC). There were two animal
studies 1992 [36] and 1993 [37] which by the authors were
interpreted as showing a peripheral inhibitory effect of
sumatriptan on primary afferents of the trigeminovascular
system but which, as mentioned above, could not exclude
an inhibitory effect in the TNC [37]. From 1996 on several
high-quality animal studies, see Table 1, demonstrated a
CNS effect of sumatriptan. In addition, it was shown that
sumatriptan induced more CNS adverse events than pla-
cebo when used in the acute treatment of migraine [2].
Among the studies, two investigations are the most con-
vincing as falsifying experiments both in animals and man:
in one study in rats sumatriptan blocked the induction of
central sensitization after an inflammatory soup on dura
most likely by presynaptic inhibition [21]. In a recent PET
investigation in six migraine patients during an actual
attack, subcutaneous sumatriptan 6 mg normalizes the
attack-related increase in brain serotonin synthesis [54].
There is a debate as to whether the anti-migraine action
of triptans is solely through peripheral effects, cranial
vasoconstriction [6, 7] and inhibition of release of neuro-
peptide from the trigeminovascular nerve endings, or
whether antinociceptive activity within the brain stem is
partly responsible [61].
Sumatriptan can most likely, in addition to a possible
peripheral trigeminovascular effect, exert an effect in the
brain stem when used for migraine treatment. The BBB is
most likely intact during migraine attacks [22, 71] and
there is therefore no need to consider a leakage of the BBB
[9] for sumatriptan to exert a CNS effect in migraine.
Finally, it is noteworthy, that the increased activity during
migraine attacks in the brain stem, as measured with PET
[72, 73], still persisted after successful treatment of migraine
attacks with subcutaneous sumatriptan. The drug was thus
unable to ‘‘extinguish’’ the ‘‘migraine generator’’ and this is
most likely the cause of headache recurrence after suma-
triptan. This is likely also the case for other brain penetrating
triptans with which recurrence also occurs [1, 2].
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